Article

Biopsy advisable in AAION if high degree of clinical suspicion present

Rochester, NY-The decision to perform a biopsy and whether the biopsy is bilateral or unilateral can be difficult in arteritic anterior ischemic optic neuropathy (AAION).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)
June 27th 2025

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress
June 26th 2025

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

36-month results from phase 1/2a clinical study of RG6501 released
June 26th 2025

36-month results from phase 1/2a clinical study of RG6501 released

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75%
June 26th 2025

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75%

© 2025 MJH Life Sciences

All rights reserved.